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IMPORTANCE Although levodopa remains themost effective oral pharmacotherapy for
Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias.
Management of such complications continues to be a significant challenge.
OBJECTIVE To investigate the efficacy and safety of safinamide (an oral aminoamide
derivative with dopaminergic and nondopaminergic actions) in levodopa-treated patients
with motor fluctuations.
DESIGN, SETTING, AND PARTICIPANTS FromMarch 5, 2009, through February 23, 2012,
patients from academic PD care centers were randomized (1:1 ratio) to receive double-blind
adjunctive safinamide or placebo for 24 weeks. All patients had idiopathic PDwith “off” time
(time whenmedication effect has worn off and parkinsonian features, including bradykinesia
and rigidity, return) of greater than 1.5 hours per day (excludingmorning akinesia). Their
pharmacotherapy included oral levodopa plus benserazide or carbidopa in a regimen that had
been stable for 4 weeks or longer. During screening, each patient’s regimen was optimized to
minimize motor fluctuations. Study eligibility required that after 4 weeks of optimized
treatment, the patients still havemore than 1.5 hours per day of off time. Adverse events
caused the premature study discontinuation of 12 individuals (4.4%) in the safinamide group
and 10 individuals (3.6%) in the placebo group.
INTERVENTIONS Patients took safinamide or placebo as 1 tablet daily with breakfast. If no
tolerability issues arose by day 14, the starting dose, 50mg, was increased to 100mg.
MAIN OUTCOMES ANDMEASURES The prespecified primary outcomewas each treatment
group’s mean change from baseline to week 24 (or last “on” treatment value) in daily “on”
time (relief of parkinsonianmotor features) without troublesome dyskinesia, as assessed
from diary data.
RESULTS At 119 centers, 549 patients were randomized (mean [SD] age, 61.9 [9.0] years; 334
male [60.8%] and 371 white [67.6%]): 274 to safinamide and 275 to placebo. Among them,
245 (89.4%) receiving safinamide and 241 (87.6%) receiving placebo completed the study.
Mean (SD) change in daily on time without troublesome dyskinesia was +1.42 (2.80) hours for
safinamide, from a baseline of 9.30 (2.41) hours, vs +0.57 (2.47) hours for placebo, from a
baseline of 9.06 (2.50) hours (least-squares mean difference, 0.96 hour; 95% CI, 0.56-1.37
hours; P < .001, analysis of covariance). Themost frequently reported adverse event was
dyskinesia (in 40 [14.6%] vs 15 [5.5%] and as a severe event in 5 [1.8%] vs 1 [0.4%]).
CONCLUSIONS AND RELEVANCE The outcomes of this trial support safinamide as an effective
adjunct to levodopa in patients with PD andmotor fluctuations to improve on time without
troublesome dyskinesia and reduce wearing off.
TRIAL REGISTRATION clinicaltrials.gov Identifier NCT00627640
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L evodopa is themost effective andwidely usedpharma-cotherapy for Parkinson disease (PD).1,2 Unfortunately,oral levodopa use is limited by the development of
motor complications (wearing off anddyskinesias),which are
related in part to the daily dosage used.3,4 Wearing off can be
managed by increasing the dose or frequency of oral le-
vodopa administration or by adding a monoamine oxidase B
(MAO-B) inhibitor, catechol O-methyltransferase (COMT) in-
hibitor, or dopamine agonist.2 However, such strategies can
increase the risk of dyskinesia.
Safinamide is a water-soluble, orally administered ami-
noamide derivative that acts as a potent, highly selective, re-
versible MAO-B inhibitor.5-7 In addition, it blocks voltage-
dependentsodiumandcalciumchannelsandreducesneuronal
glutamate release.8 Inearly clinical studies, itwas found to im-
provemotor control in patients with PDwho received it as an
add-on treatment to a dopamine agonist9-11 or as an adjunct
to levodopa.10 We describe the results of a phase 3 trial of sa-
finamideasanadjunct to levodopa inpatientswithPDandmo-
tor fluctuations who were taking levodopa.
Methods
The Safinamide Treatment as Add-on to Levodopa studywas
adouble-blind,parallel-group,24-week trialof safinamide (50-
100mg/d orally) vs placebo in patients taking stable dosages
of levodopa and concomitant PDmedications. The complete
trialprotocol canbe found inSupplement 1.Thestudywascon-
ducted in accordance with the study protocol and its amend-
ments, the Declaration of Helsinki,12 the International Con-
ference onHarmonisationHarmonised Tripartite Guideline13
for good clinical practices, and all applicable local regulatory
requirements, including institutional review board approval.
Study investigators fully explained the trial to all patients and,
before study participation, all patients provided written in-
formed consent.
Study Participants
In 21 countries in Europe, the Asia-Pacific region, and North
America, 126centersscreened851patients fromMarch5,2009,
throughFebruary 23, 2012.All patientswere required tobe 30
to 80 years old and have a diagnosis of idiopathic PD by clini-
cal evaluation and Queen Square Brain Bank criteria, with a
longer than3-year duration sincediagnosis, aHoehnandYahr
rating of stages 1 to 4 during an “off” phase (timewhenmedi-
cation effect has worn off and parkinsonian features, includ-
ingbradykinesia andrigidity, return), anddailyoff timegreater
than 1.5hours (excludingmorningakinesia). Patientswerealso
required to be levodopa responsive and following an oral le-
vodopa regimen (3-10 doses per day of any levodopa prepa-
ration,withorwithout aCOMT inhibitor) that hadbeen stable
for 4weeks. Their PDpharmacotherapy could include adopa-
mine agonist, anticholinergic, COMT inhibitor, and/or aman-
tadine at stabledosage. Patientswere excluded for severe, dis-
abling peak-dose or biphasic dyskinesia and/or wide or
unpredictable symptom fluctuations. The study’s full exclu-
sion criteria are summarized in the eTable in Supplement 2.
Study Design
During a 10-day screening period, each patient’s PD pharma-
cotherapy was adjusted to minimize motor fluctuations. Pa-
tients then entered an observation phase that lasted 4 weeks
(or longer, if needed to permit 4-week observation of an
unchanged regimen). At the study’s conclusion (the patient’s
baseline visit), eligibility required that the patient still be ex-
periencing daily off time greater than 1.5 hours.
In adouble-blind fashion, enrolledpatientswere random-
ized (1:1) to receive safinamide or matching placebo, taken as
1 tablet daily with breakfast (Figure 1). They underwent post-
baseline efficacy and safety assessments at weeks 2, 4, 8, 12,
18, and 24 (or premature discontinuation). In addition, they
or their caregiverswere telephoned ondays 7 and 21 to assess
study drug tolerability. If there were no tolerability issues by
day 14, the starting dosage, 50 mg/d, was increased to 100
mg/d. Patients were permitted to continue standard oral PD
pharmacotherapies at stable dosage (except MAO-B inhibi-
tors, which could not be used within 8 weeks before screen-
ing). Patients requiring an increase in antiparkinsonian treat-
ment before week 24 were asked to participate in all further
assessments. In such cases, the assessment used for the pri-
mary efficacy outcome was performed before the dose in-
crease.Patients completing24weekswereeligible foranopen-
label extension study. Those not continuing had their study
drug dosage tapered during a 1-week period (week 25), with a
follow-up safety assessment 4 weeks later (week 29).
Randomization andMasking
At patient enrollment, study site personnel contacted a cen-
tralized, computerized interactive voice-response system,
whichcreated the study’s randomization scheme (stratifiedby
country or region) and assigned each patient the appropriate
medication, identified by kit number and provided for each
dose level of active drug or placebo as matching tablets in
matching blister packs. The randomization code remained
blinded throughout the study.
EfficacyMeasures
Theprimaryefficacyoutcomewaschangefrombaselinetoweek
24 in mean daily “on” time (relief of parkinsonian motor
features) without troublesome dyskinesia, as recorded by
patients or caregivers in a diary14 maintained for the 3 days
Key Points
Question Is safinamide a beneficial treatment for motor
fluctuations in patients using oral levodopa for the treatment of
Parkinson disease?
Findings In this 24-week, randomized clinical trial, 549 patients
hadmore than 1.5 hours per day of “off” time despite
pharmacotherapy optimized tominimize motor fluctuations.
Safinamide taken once daily significantly increased daily “on” time
without troublesome dyskinesia by amean 1.42 hours vs 0.57 hour
for placebo.
Meaning The study supports the use of safinamide as an effective
adjunct to levodopa for fluctuating Parkinson disease.
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preceding the baseline visit and each postbaseline visit. The
diaries characterized each 30-minute interval during the
18-hour day (0600 to 2400 hours) as on time, on time with
nontroublesome dyskinesia, on time with troublesome dys-
kinesia, off time, or time asleep. To optimize their accuracy,
all diary data analyses were based on entries for the second
and third days.
Secondary efficacy outcomes were based on diary en-
tries,UnifiedParkinson’sDiseaseRatingScale (UPDRS) scores,
Clinical Global Impression–Change (CGI-C) ratings, Clinical
Global Impression–Severity (CGI-S) ratings, PatientGlobal Im-
pression–Change (PGI-C) ratings, 39-item Parkinson Disease
Questionnaire (PDQ-39) scores, EuroQoL 5 dimensions
(EQ-5D) scores, change in levodopa daily dosage, Dyskinesia
Rating Scale (DRS) scores, andCogtest PDBattery scores. Five
suchoutcomes, includingmeanchange indailyoff time,mean
change in UPDRS Part III (motor examination) and Part II (ac-
tivities of daily living) scores during an on phase, the propor-
tion of patients with an improved CGI-C rating, and mean
change in PDQ-39 summary index score, were predefined as
key secondary outcomes. Tertiary outcomes were based on
Hoehn and Yahr stage; Hamilton Rating Scale of Depression,
17-item grid version, scores; andMini-Mental State Examina-
tion scores.
Efficacy Analyses
Among all randomized patients (intention-to-treat popula-
tion), the primary efficacy outcomewas tested by analysis of
covariance, with treatment and country or region as fixed ef-
fects andbaselinevalue as the covariate. For patientswhodis-
continued or changed use of their PD medication, a week 24
value was imputed by a last observation carried forward ap-
proach. If the difference between treatment groups was sta-
tistically significant (P ≤ .05), the key secondary end points
were to be analyzed hierarchically, unless a difference be-
tween groups was statistically nonsignificant, in which case
all further analyseswould be performed only to obtain nomi-
nal P values. The same analysis of covariancemodel used for
the primary efficacy analysis was used for all other out-
comes, exceptCGI-C andPGI-C scores atweek24,whichwere
assessed by analysis of variance with fixed effects for treat-
ment and region, and theproportionofpatientswith improve-
ment on the CGI-C, whichwas assessed by logistic regression
with treatment and region as fixed effects. The resulting odds
ratio was subjected to theWald χ2 test. As a sensitivity analy-
sis, change in daily on time was examined using a mixed-
effects repeated-measures model, with no imputation of
missing data.
SafetyMeasures
The safety of safinamide was assessed by summary statistics
for all patients exposed to study medication (safety popula-
tion). Safetymeasures included treatment-emergent adverse
events (TEAEs), as classified by the Medical Dictionary for
Regulatory Activities, version 13.015; serious adverse events
(SAEs); anddiscontinuations attributable toTEAEs. They also
includedphysical, neurologic, ophthalmologic, anddermato-
logic examinations; 12-lead electrocardiography; and clinical
laboratory tests. The incidence of impulse control disorders
was assessed by the Questionnaire for Impulsive-Compul-
Figure 1. Trial Profile
851 Patients assessed 
for eligibility
302 Excluded
249
38
15
Not meeting inclusion criteria
Refused to participate
Other reasons
549 Randomized
274 Randomized to safinamide 275 Randomized to placebo
274 Received safinamide
as randomized
275 Received placebo as 
randomized
274 Included in analysis 275 Included in analysis
29 Discontinued prematurely
12
6
4
3
1
1
1
1
TEAEs
Withdrew consent
Inclusion or exclusion 
criteria not met
Lost to follow-up
Death
Investigator or medical 
monitor decision
Nonadherence
Transportation problem
34 Discontinued prematurely
18
10
2
2
2
Withdrew consent
TEAEs
Death
Investigator or medical 
monitor decision
Lost to follow-up
245 Completed study 241 Completed study
TEAEs indicates treatment-emergent
adverse events.
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sive Disorders in Parkinson Disease,16 and daytime sleepi-
ness was assessed by the Epworth Sleepiness Scale.
Sample-Size Calculation
On the basis of a 2-sided, 2-sample t test applied to findings
of the Parkinson’s Rasagiline: Efficacy and Safety in the
Treatment of Off (PRESTO) study,17 a minimum of 416
patients (208 per treatment group) would provide 90%
power or greater to detect a difference of 0.75 hour in daily
on time between groups, assuming an SD of 2.35 hours (for
change from baseline to week 24) and a type I error rate of
5%. Assuming a dropout (or missing data) rate of 14%, a
minimum of 484 patients (242 per treatment group) would
need to be randomized.
Results
Participant Disposition and Characteristics
At 119 centers, 549 patients were randomized (mean [SD] age,
61.9 [9.0] years; 334 male [60.8%] and 371 white [67.6%]):
274 to safinamide and 275 to placebo (Figure 1). Among
them, 245 patients (89.4%) in the safinamide group and 241
patients (87.6%) in the placebo group completed the study. In
both groups, the most common reason for premature discon-
tinuation was TEAEs (12 patients [4.4%] in the safinamide
group and 10 patients [3.6%] in the placebo group). During
the study, 11 patients (4.0%) taking safinamide and 21
patients (7.6%) taking placebo required a change in antipar-
kinsonian treatment.
The mean (SD) PD duration was 8.9 (4.6) years, and the
mean (SD) levodopa dosage was 776.5 (423.8) mg/d, with
408 patients (74.3%) also taking a dopamine agonist, 166
(30.2%) taking amantadine, 95 (17.3%) taking anticholiner-
gics, and 83 (15.1%) taking entacapone. Baseline characteris-
tics revealed no significant differences between the treat-
ment groups (Table 1).
Study Drug Exposure
Mean (SD) studydrug exposurewas 162.3 (37.7) days in the sa-
finamide group and 160.7 (37.5) days in the placebo group. At
day 14, a total of 219 of 241 patients (90.9%) in the safinamide
groupand225of239patients (94.1%) in theplacebogroupwere
prescribed the 100-mg target dose.
Table 1. Baseline Characteristics of the Patients in the Intention-to-Treat Population
Characteristic
Safinamide Group
(n = 274)
Placebo Group
(n = 275) P Valuea
Age, mean (SD), y 61.7 (9.0) 62.1 (8.9) .55
Sex, No. (%)
Male 171 (62.4) 163 (59.3)
.45
Female 103 (37.6) 112 (40.7)
Race, No. (%)
White 183 (66.8) 188 (68.4)
.35Asian 88 (32.1) 85 (30.9)
Other 3 (1.1) 2 (0.7)
Region, No. (%)
Western Europe 109 (39.8) 110 (40.0)
>.99
Asia-Pacific 84 (30.7) 84 (30.5)
North America 51 (18.6) 51 (18.5)
Eastern Europe 30 (10.9) 30 (10.9)
Weight, mean (SD), kg 72.5 (16.4)b 71.0 (15.8)c .21
Hoehn and Yahr stage,d mean (SD) 2.5 (0.6) 2.5 (0.6)c .80
Levodopa dosage, mean (SD), mg/d 760.8 (445.9)e 792.3 (400.7)b .39
UPDRS score, mean (SD)
Part I 1.3 (1.3) 1.3 (1.5) .89
Part IIf 10.0 (5.6)g 10.4 (6.3)b .36
Part IIIf 22.4 (11.8) 23.4 (12.9) .38
Part IV 5.9 (2.9) 6.0 (2.9) .96
CGI-S rating, No. (%)
Healthy/not at all ill 0 0b
.10
Borderline ill 7 (2.6) 4 (1.5)b
Mildly ill 54 (19.7) 45 (16.5)b
Moderately ill 162 (59.1) 160 (58.8)b
Markedly ill 48 (17.5) 60 (22.1)b
Severely ill 3 (1.1) 3 (1.1)b
MMSE score, mean (SD) 28.7 (1.5) 28.6 (1.6) .91
GRID-HAMD score, mean (SD) 4.7 (4.0) 5.0 (4.1) .48
Abbreviations: CGI-S, Clinical Global
Impression–Severity scale;
GRID-HAMD, Hamilton Rating Scale
of Depression, 17-item grid version;
MMSE, Mini-Mental State
Examination; UPDRS, Unified
Parkinson’s Disease Rating Scale.
a For continuous variables, 2-way
analysis of variance with treatment
and region as fixed effects; for
categorical variables,
Cochran-Mantel-Haenszel test
stratified by region.
b n = 272.
c n = 274.
dDuring an “off” phase (the time
whenmedication effect has worn
off and parkinsonian features,
including bradykinesia and rigidity,
return).
e n = 273.
f During an “on” phase (the time
when patients experience relief of
parkinsonianmotor features).
g n = 271.
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Efficacy Outcomes
Atweek24, themean (SD) increase in total daily on timewith-
out troublesome dyskinesia (primary efficacy outcome) was
+1.42 (2.80) hours in the safinamide group and +0.57 (2.47)
hours in the placebo group (least-squares [LS] mean differ-
ence, 0.96 hour; 95% CI, 0.56-1.37 hours; P < .001). In the
mixed-effects repeated-measures model, the mean (SD) in-
crease was +1.61 (2.81) vs +0.17 (2.38) hours (LS mean differ-
ence, 0.93 hour; 95% CI, 0.50-1.36 hours; P < .001).
Among key secondary outcomes (Table 2), the mean (SD)
decrease in daily off timewas –1.56 (2.35) vs –0.54 (2.21) hours
(LSmeandifference, –1.03hours; 95%CI, –1.40 to –0.67hours;
P < .001).Mean (SD)decrease (improvement) inUPDRSPart III
score rated during an on phase was –3.43 (7.72) vs –1.83 (8.23)
(LS mean difference, –1.82; 95% CI, –3.01 to –0.62; P = .003).
However,mean (SD) change inUPDRSPart II scorewasnonsig-
nificantat–1.07 (3.63)vs–0.75 (3.95) (LSmeandifference, –0.43;
95% CI, –1.02 to 0.16; P = .15). The proportion of patients with
improvement (scores of 1, 2, or 3) onCGI-Cwas 57.7%vs 41.8%
(oddsratio, 1.92;95%CI, 1.36-2.70;nominalP < .001).Mean(SD)
decrease (improvement) in PDQ-39 summary index score was
–3.17 (10.86)vs –0.68 (10.51) (LSmeandifference, –2.33;95%CI,
–3.98 to –0.68; nominal P = .006).
Amongother secondary findings (Table2),mean improve-
ments in thesafinamidegroup(vsplacebo)hadnominalP ≤ .05
for CGI-C, PGI-C, and CGI-S scores, off time after themorning
levodopa dose, EQ-5D index score, and levodopa daily dos-
age, representingdecreases in 18patients (6.6%) taking safin-
amideand4patients (1.5%) takingplacebo.On theUPDRSPart
IV (complicationsof therapy), the safinamidegrouphadanap-
proximately0.1-point increase (worsening) in scores on items
32 to 34 and 32 to 35. For both increases, the LS mean differ-
ence fromplacebowas0.26point (95%CI,0.02-0.50 for items
32 -24and0.01-0.52 for items32-35;nominalP = .04 forboth).
In a post hoc efficacy analysis, the safinamide group ex-
hibited a significant increase vs placebo indaily on timewith-
out troublesomedyskinesiawhile receiving treatmentwith50
mg/d at the end of week 2, the first postbaseline assessment
time point (mean [SD], 1.04 [2.24] hours vs 0.40 [1.81] hours;
P < .001 by paired, 2-sided t test). This benefit was main-
tained at all subsequent time points (Figure 2).
Safety
Overall, 186 patients (67.9%) in the safinamide group and 190
patients (69.1%) in theplacebogroupreportedTEAEs (Table3).
Among the TEAEs most frequently reported, dyskinesia was
more common in the safinamide group than in the placebo
group (40 [14.6%] vs 15 [5.5%]). The incidence of TEAEs rated
as severe was lower in the safinamide group than in the pla-
cebo group (19 [6.9%] vs 25 [9.1%]). However, dyskinesiawas
reported as severe in 5patients (1.8%) taking safinamide com-
pared with 1 patient (0.4%) taking placebo.
Eighteen patients (6.6%) taking safinamide and 26
patients (9.5%) taking placebo experienced treatment-
emergent SAEs. The SAEs in more than 1 patient in either
groupwere breast cancer and visual hallucinations, each in 2
patients taking safinamide; and diarrhea, hallucinations,
and myocardial ischemia, each in 2 patients taking placebo.
Fourteen patients (5.1%) in the safinamide group and 12
patients (4.4%) in the placebo grouphadTEAEs that led to in-
terruption of study drug treatment. In the safinamide group,
12 of these patients discontinued participation in the trial, 1
decided to withdraw, and 1 remained in the trial. In the pla-
cebogroup, 10patients discontinuedparticipation in the trial,
1 decided to withdraw, and 1 died. Six patients (2.2%) taking
safinamideand 1 (0.4%) takingplacebo interrupted their treat-
ment because of nervous system events: dyskinesia in 3 pa-
tients in the safinamide group, PD worsening in 2 patients in
the safinamide group, paraesthesia in 1 patient in the safin-
amide group, and dizziness in 1 patient in the placebo group.
Therewere3deaths: 1 (0.4%) in thesafinamidegroup(PDwors-
ening, considered unlikely to be related to studymedication)
and 2 (0.7%) in the placebo group (myocardial ischemia and
acute lymphocytic leukemia).
The treatment groups exhibited no clinically meaningful
mean changes in physical findings, laboratory values, or elec-
trocardiographic data, and abnormal postbaseline shifts had
similar incidencesacrossgroups.Questionnaire for Impulsive-
Compulsive Disorders in Parkinson Disease and Epworth
Sleepiness Scale total scores showed little change. (In the sa-
finamide group, the mean changes were –0.03 and –0.28, re-
spectively.) Results of ophthalmologic examinations were
similar in both groups and revealed no significantworsening.
Discussion
At 100mg/d, safinamide significantly increasedmeandailyon
timewithout troublesomedyskinesia by0.96hourmore than
placebo in patients taking a stable dose of levodopa. The in-
creasewasestablishedby2weeksandwassubsequentlymain-
tained. In addition, safinamide reduced mean daily off time,
improved motor function (UPDRS Part III), improved quality
of life (PDQ-39, EQ-5D), and revealed a global benefit (CGI).
Early-morning off time was also reduced.
Overall, the study’s diary data suggest safinamide effects
similar or superior to those reported for MAO-B or COMT in-
hibitors evaluated as levodopa adjuncts to reduce off time for
advanced PD. Notwithstanding the limitations of cross-trial
comparisons, includingpotentialdifferences inpatients’demo-
graphic andPDcharacteristics, the reduction inoff time for the
safinamidegroup, 1.03hoursvsplacebo, identifiedat24weeks
as a secondary efficacy outcome,may be comparedwith that
of the26-weekPRESTOstudy,17 inwhich the reductionvspla-
cebowas 0.49 hour for 0.5mg of rasagiline and 0.94 hour for
1mg of rasagiline (as the primary efficacy outcomes), and the
18-week Lasting Effect in Adjunct Therapy With Rasagiline
Given Once Daily (LARGO) study,18 in which it was 0.78 hour
for 1mgof rasagiline and0.80hour for entacapone (as thepri-
mary efficacy outcomes). For on-time improvement, the sa-
finamide outcome, an increase of 0.96 hour vs placebo in on
time without troublesome dyskinesia (primary efficacy out-
come), was accompanied by a statistically insignificant in-
crease of 0.08 hour in on time with troublesome dyskinesia
(as an exploratory outcome). In the PRESTO study,17 the total
increase was 0.56 hour for 0.5 mg of rasagiline, with no
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Table 2. Efficacy Findings in the Intention-to-Treat Population (Last Observation Carried Forward)
Outcome
Safinamide Group, Mean (SD)
(n = 274)
Placebo Group, Mean (SD)
(n = 275) LS MeanDifference in
Change (95% CI)a P ValueaBaseline Week 24 Change Baseline Week 24 Change
Primary Outcome
“On” time without
troublesome dyskinesia,b h/d
9.30 (2.41) 10.73 (2.75) +1.42 (2.80) 9.06 (2.50) 9.63 (2.77) +0.57 (2.47) +0.96
(+0.56 to +1.37)
<.001
Key Secondary Outcomes
“Off” time,b h/d 5.34 (1.97) 3.77 (2.56) –1.56 (2.35) 5.38 (2.01) 4.84 (2.59) –0.54 (2.21) –1.03
(–1.40 to –0.67)
<.001
UPDRS Part III scorec 22.26 (11.66) 18.83 (10.87) –3.43 (7.72) 23.05 (12.65) 21.22 (11.78) –1.83 (8.23) –1.82
(–3.01 to –0.62)
.003
UPDRS Part II scorec 9.97 (5.53) 8.90 (5.44) –1.07 (3.63) 10.43 (6.29) 9.68 (5.94) –0.75 (3.95) –0.43
(–1.02 to +0.16)
.15
Patients with improvement on
CGI-C, %d
NA 57.7 NA NA 41.8 NA 1.92
(1.36 to 2.70)e
<.001e,f
PDQ-39 score 27.47 (14.61) 24.31 (13.73) –3.17 (10.86) 26.94 (14.83) 26.26 (14.92) –0.68 (10.51) –2.33
(–3.98 to –0.68)
.006e
Other Secondary Outcomes
CGI-C rating NA 3.31 (1.10) NA NA 3.76 (1.02) NA –0.44
(–0.62 to –0.27)f
<.001e,g
CGI-S rating 3.95 (0.72) 3.75 (0.79) –0.20 (0.69) 4.05 (0.70) 3.94 (0.72) –0.11 (0.67) –0.13
(–0.24 to –0.03)
.01e
Off time after the morning
levodopa dose, h/d
0.83 (0.57) 0.57 (0.56) –0.26 (0.59) 0.86 (0.65) 0.76 (0.71) –0.09 (0.79) –0.18
(–0.28 to –0.09)
<.001e
DRS score 2.79 (3.50) 2.67 (2.99) –0.11 (2.86) 2.57 (3.08) 2.33 (2.69) –0.24 (2.50) +0.23
(–0.14 to +0.60)
.22e
Change in levodopa dose, % NA NA –1.11 (11.43) NA NA +0.78 (6.45) –1.89
(–3.44 to –0.33)
.02e
PGI-C rating NA 3.28 (1.10) NA NA 3.67 (1.01) NA –0.40
(–0.57 to –0.22)f
<.001e,g
UPDRS Part IV items 32-34
score
1.89 (1.98) 1.99 (2.08) +0.10 (1.79) 1.89 (1.99) 1.74 (1.81) –0.15 (1.38) +0.26
(+0.02 to +0.50)
.04e
UPDRS Part IV items 32-35
score
2.18 (2.12) 2.27 (2.17) +0.08 (1.86) 2.24 (2.12) 2.04 (1.95) –0.20 (1.47) +0.26
(+0.01 to +0.52)
.04e
EQ-5D index score 0.68 (0.18) 0.71 (0.18) +0.03 (0.19) 0.67 (0.20) 0.65 (0.21) –0.03 (0.19) +0.06
(+0.03 to +0.09)
<.001e
Cogtest PD Battery scores
Auditory No. sequencing –0.65 (0.93) –0.73 (0.94) –0.08 (0.95) –0.62 (0.98) –0.53 (0.95) +0.09 (1.07) –0.19
(–0.33 to –0.05)
.01e
Spatial working memory 2.81 (3.95) 2.60 (3.26) –0.21 (4.11) 2.34 (3.33) 2.57 (3.59) +0.24 (3.66) –0.14
(–0.66 to +0.38)
.60e
Strategic target detection 1.01 (1.32) 1.28 (1.39) +0.27 (1.65) 1.08 (1.36) 1.21 (1.30) +0.13 (1.61) +0.09
(–0.13 to +0.30)
.44e
Word list memory –0.91 (1.50) –0.70 (1.61) +0.21 (1.45) –0.92 (1.43) –0.65 (1.38) +0.27 (1.31) –0.05
(–0.26 to +0.15)
.61e
Symbol digit substitution –2.54 (0.86) –2.50 (0.92) +0.05 (0.77) –2.62 (0.86) –2.48 (0.87) +0.14 (0.68) –0.07
(–0.18 to +0.04)
.24e
Tower of London –0.19 (0.99) –0.02 (0.97) +0.17 (1.03) –0.18 (0.99) 0.08 (0.91) +0.26 (1.00) –0.10
(–0.24 to +0.04)
.16e
Word list memory delayed –1.09 (1.58) –1.01 (1.55) +0.09 (1.55) –1.15 (1.57) –0.99 (1.45) +0.16 (1.44) –0.05
(–0.26 to +0.17)
.68e
Tertiary Outcomes
Hoehn and Yahr stage 2.48 (0.59) 2.43 (0.58) –0.05 (0.45) 2.49 (0.61) 2.44 (0.62) –0.05 (0.51) –0.01
(–0.08 to +0.07)
.88e
GRID-HAMD score 4.74 (4.04) 4.82 (4.33) +0.07 (3.61) 4.95 (4.09) 5.28 (4.91) +0.32 (4.11) –0.31
(–0.93 to +0.30)
.32e
MMSE score 28.66 (1.46) 28.46 (1.93) –0.20 (1.50) 28.64 (1.58) 28.59 (1.60) –0.05 (1.61) –0.14
(–0.39 to +0.10)
.26e
Abbreviations: CGI-C, Clinical Global Impression–Change; CGI-S, Clinical Global Impression–Severity; DRS, Dyskinesia Rating Scale; EQ-5D, EuroQoL 5 dimensions;
GRID-HAMD, Hamilton Rating Scale of Depression, 17-item grid version; LS, least-squares;MMSE,Mini-Mental State Examination; NA, not applicable; PD, Parkinson
disease; PDQ-39, 39-itemParkinsonDiseaseQuestionnaire; PGI-C, Patient Global Impression–Change; UPDRS, Unified Parkinson’s Disease Rating Scale.
a Calculated, unless noted otherwise, from an analysis of covariancemodel with treatment and region as fixed effects and baseline value as covariate.
b Frompatient diary data. “Off” time is defined as the timewhenmedication effect hasworn off and parkinsonian features, including bradykinesia and rigidity, return.
c During an “on” phase (the time when patients experience relief of Parkinsonianmotor features).
d Scores of 1, 2, or 3.
e Nominal P value, following a nonsignificant difference between treatment groups on an earlier test in the study’s hierarchical test sequence.
f Odds ratios and 95% CIs estimated by logistic regressionmodel with treatment and region as fixed effects; P value calculated with theWald χ2 test.
g Calculated from an analysis of variancemodel with fixed effects for treatment and region.
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increase in troublesomedyskinesia.For 1mgof rasagiline,how-
ever, on timewith troublesomedyskinesia accounted for 32%
of a total increase of 1.15 hours. In the LARGO study,18 it ac-
counted for 21% of a total 1.08-hour increase for 1 mg of
rasagiline and 17% of a total 1.03-hour increase for entaca-
pone. In the present trial, the safinamide CGI outcome was
–0.44 vs placebo (Table 2). In the PRESTO study, it was –0.68
for0.5mgof rasagiline and–0.39 for 1.0mgof rasagiline,17 and
in the LARGO study, it was –0.49 for 1.0 mg of rasagiline and
–0.36 for entacapone.18
The outcomes of the present trial support those of a previ-
ousdouble-blindstudyofsafinamideasanadjunct to levodopa,
inwhich669patientswithmotor fluctuations following stable
regimensof levodopaandotherPDpharmacotherapieswereran-
domized toadjunctiveplaceboor50or 100mg/dof safinamide
for24weeks.19Safinamidesignificantly increaseddailyontime
without troublesomedyskinesiabyanLSmean,comparedwith
placebo, of 0.51 hour for 50mg/d and 0.55 hour for 100mg/d.
Significantreductionswereobservedindailyoff time, inoff time
after firstmorning levodopadose, and inUPDRSPart III scores
while on. After an additional 18 months, the benefits of safin-
amide at 100 mg/d remained significant vs placebo by out-
comemeasures, including daily on timewithout troublesome
dyskinesia, daily off time, UPDRS Part III score, and PDQ-39
score.20
In thepresent trial, nondiarymeasuresofdyskinesia in the
safinamide group revealed either no change (DRS score) or a
small increase of nominal significance (UPDRS Part IV dyski-
nesia subscores).AsaTEAE,dyskinesiawas reportedmore fre-
quently with safinamide than with placebo. Its incidence
(14.6% during 24 weeks vs 5.5% for placebo) resembled that
reported for rasagiline inpatientswith fluctuatingPD(18%dur-
ing 26 weeks vs 10% for placebo17). In the previous safin-
amide trial, there was no apparent association between dos-
age and the frequency of dyskinesias, whichwas 21.1% for 50
mg/d and 18.3% for 100 mg/d compared with 12.6% for pla-
cebo at 24 weeks19 and 31.2% for 50 mg/d and 27.8% for 100
mg/d compared with 21.7% for placebo at 2 years.20 In both
studies,19,20 safinamidewas generally well tolerated, as indi-
cated by high study completion rates (approximately 89% in
the present trial) and low rates of safinamide treatment dis-
continuation attributable to TEAEs (approximately 5% in the
present trial).
Figure 2. Change in “On” TimeWithout TroublesomeDyskinesia During
Double-blind Treatment in the Intention-to-Treat Population
(Last Observation Carried Forward)
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Results are based on patient diary data. “On” time indicates when patients
experience relief of parkinsonianmotor features. Error bars indicate SE.
a P < .001 (unpaired, 2-sample t test).
Table 3. TEAEs in the Safety Population
TEAE
No. (% of Group)
Safinamide Group
(n = 274)
Placebo Group
(n = 275)
Summary
Any TEAE 186 (67.9) 190 (69.1)
Mild 163 (59.5) 161 (58.5)
Moderate 85 (31.0) 72 (26.2)
Severe 19 (6.9) 25 (9.1)
Any study drug–related
TEAEa
78 (28.5) 76 (27.6)
Any SAE 18 (6.6) 26 (9.5)
Any study drug–related SAEa 3 (1.1) 6 (2.2)
Any TEAE causing
discontinuation from study
12 (4.4) 10 (3.6)
Death 1 (0.4) 2 (0.7)
By preferred termb
Dyskinesia 40 (14.6) 15 (5.5)
Fall 18 (6.6) 10 (3.6)
Urinary tract infection 17 (6.2) 12 (4.4)
Nausea 16 (5.8) 15 (5.5)
Headache 12 (4.4) 17 (6.2)
Constipation 11 (4.0) 11 (4.0)
Somnolence 10 (3.6) 8 (2.9)
Insomnia 10 (3.6) 5 (1.8)
Back pain 9 (3.3) 14 (5.1)
Nasopharyngitis 9 (3.3) 11 (4.0)
Hypoesthesia 8 (2.9) 2 (0.7)
Arthralgia 7 (2.6) 13 (4.7)
Dizziness 7 (2.6) 8 (2.9)
Diarrhea 7 (2.6) 7 (2.5)
Parkinson disease 7 (2.6) 5 (1.8)
Dyspepsia 7 (2.6) 3 (1.1)
Hallucination 6 (2.2) 6 (2.2)
Anxiety 6 (2.2) 4 (1.5)
Cough 6 (2.2) 3 (1.1)
Hypertension 4 (1.5) 6 (2.2)
Fatigue 3 (1.1) 8 (2.9)
Muscle spasms 3 (1.1) 6 (2.2)
Abdominal pain upper 0 6 (2.2)
Abbreviations: SAE, serious adverse event; TEAE, treatment-emergent adverse
event.
a Recorded relation to study drug was probable, possible, or missing.
b Listed types, by Medical Dictionary for Regulatory Activities, version 13.015
preferred term, are all those reported in more than 2.0% of either treatment
group.
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Limitations
Limitations to the interpretation of the present study’s out-
comes include the study’s duration of 24 weeks and its test-
ingofonly 1prespecifieddosage level (100mg).The studyalso
didnotobtainovernightdiarydataanddidnotanalyze thedata
from the first day of each 3-day diary-keeping period.
Conclusions
Themanagement of motor complications in PD remains a sig-
nificant challenge in which all available pharmacologic
options carry the riskof inducingorexacerbatingdyskinesias.2
In the present study, safinamide increased on time and de-
creased off time to levels comparable to those seen forMAO-B
and COMT inhibitors and had a low risk of inducing or exacer-
batingdyskinesia categorized as troublesome. For safinamide,
theseeffectsmayberelated todopaminergicandnondopamin-
ergic drug actions. It is notable that in a nonprimate model of
levodopa-induced dyskinesias, safinamide reduced the inten-
sity and duration of dyskinesias and also prolonged themotor
benefits of levodopa.21 Despite this study’s limitations, it pro-
vides evidence that supports safinamide as an effective once-
daily adjunct to levodopa for fluctuatingPD.Weanticipate that
the results are generalizable across thePDpopulation and sug-
gest that safinamide offers an additional option for the control
of motor fluctuations by oral medication before considering
infusion therapies or deep brain stimulation.
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